COPENHAGEN, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Zealand Pharma (Copenhagen:ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that its partner Sanofi has submitted a marketing authorization application (MAA) for Lyxumia(R) (lixisenatide) in Europe. Sanofi announced the news in the company's Q3 report this morning. Lixisenatide is a once-daily GLP-1 receptor agonist discovered by Zealand Pharma and licensed to Sanofi, which is completing Phase III development of the drug as a new treatment for Type-2 diabetes.
